Open AccessP591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT‐3 INHIBITOR, IN PATINETS WITH FLT3‐MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
Author(s) -
Yu W.,
Wei X.,
Ge Z.,
Li Y.,
Jiang Z.,
Yang L.,
Lin L.,
Yao Y.,
Deng X.,
Du X.,
Li Y.,
Chen T.,
Feng X.,
Zhou J.,
Hou M.,
Fu R.,
Lan J.,
Hu X.,
Huang S.,
Wang J.,
Du X.,
Yang H.,
Yang H.,
Wang H.,
Zheng L.,
Wang Z.,
Liu B.,
Kang N.,
Zhuang Y.,
Zhang Y.,
Jin J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845252.68424.50
Subject(s) - tolerability , medicine , myeloid leukemia , adverse effect , refractory (planetary science) , gastroenterology , hematopoietic stem cell transplantation , transplantation , phases of clinical research , pharmacology , oncology , chemotherapy , biology , astrobiology